One Line Pitch: Cubresa builds SPECT and PET cameras for retro fit to current single imaging devices such as CT scanners and MRI.
Business Summary: The Company is building small SPECT and PET cameras for pre-clinical (animal) researchers who research the effectiveness of drugs in tumor management.
Management: James Schellenberg graduated from the University of Manitoba in 1990 with a Ph.D. (EE). His expertise stems from 20 years of start-up experience, which includes 12 years in telecom and 8 years in medical imaging, including the position of VP-R&D for IMRIS. Harry Ethans is a seasoned M&A executive.
Customer Problem: Clinical research organizations (CROs) need to migrate to multi-modal imaging to provide a competitive service. Many have existing infrastructure which has only single-purpose imaging capacity. The current solution is to dispose of existing devices single-purpose devices and purchase new devices with SPECT and PET embedded by the OEM.
Product / Services: Cubresa manufactures, sells and services retro fit SPECT and PET cameras including the electronics and software for integration.
Market Value Propositions: Cost-effective approach for CROs to update aging infrastructure.
Target Market and Customers: Our target market are CROs with single-modality imaging devices. This customer base represents a total of $12 billion of sales for Cubresa.
Business Model: Cubresa invents, designs, manufactures and markets the equipment to channel partners and directly to CROs depending on the geographic region.
Competitive Advantage: This is a unique patented approach that offers co-registered MRI and Gamma images for improved pre-clinical analysis.
Competitors: Bruker’s Albira, VECTor and MEdiso are all new devices which offer multi-modal imaging. Cubresa is the only after-market addition currently available.
Next Steps: Secure a second technology patent in PET and an international customer.